Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

203.35
-4.3300-2.08%
Pre-market: 204.751.40+0.69%07:47 EDT
Volume:810.66K
Turnover:165.29M
Market Cap:43.59B
PE:-22.79
High:207.84
Open:205.85
Low:202.59
Close:207.68
52wk High:224.31
52wk Low:42.18
Shares:214.34M
Float Shares:185.00M
Volume Ratio:0.58
T/O Rate:0.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.72
PE(LYR):-34.18

Loading ...

Pancreatic Cancer Milestone: FDA Approves RevMed's Targeted Drug; 2032 Sales Seen Above $9B

Options & Short Sell
·
Aug 27

Revolution Medicines Earns Buy as RASONQUE FDA Approval and Strong Pricing Outlook Drive Price Target Increase to $315

TIPRANKS
·
Aug 27

Revolution Medicines Prices Metastatic Pancreatic Cancer Drug Rasonque at $39,800 a Month

MT Newswires Live
·
Aug 27

Revolution Medicines to Charge $39,800 a Month for Pancreatic Cancer Drug, Bloomberg Reports

MT Newswires Live
·
Aug 27

Revolution Medicines - Rasonque is NOW Commercially Available in the U.S. at a Wholesale Acquisition Cost of $39,800 for a 30-Day Supply - Conf Call

THOMSON REUTERS
·
Aug 27

Revolution Medicines Posts Investor Presentation on Rasonque FDA Approval

Reuters
·
Aug 27

Revolution Medicines prices Rasonque at $39,800 for 30-day supply

TIPRANKS
·
Aug 27

Revolution Medicines announces FDA approval of Rasonque in adults

TIPRANKS
·
Aug 27

Revolution Medicines, - Rasonque 300 Mg Once-Daily Oral Tablets NOW Available in the U.S.

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ Rasonque™ (Daraxonrasib), the First Broad Ras-Targeted Medicine in Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 27

U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer

GlobeNewswire
·
Aug 27

FDA Approves Drug for Pancreatic Cancer in Incredible Moment for Deadly Disease

Dow Jones
·
Aug 26

Movement Alert|Revolution Medicines, Inc. Falls 5.34% in Regular Trading, Trading at $200.13

Market Focus
·
Aug 26

US FDA Approves Revolution Medicines' Pancreatic Cancer Drug

Reuters
·
Aug 26

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Aug 26

Revolution Medicines CEO Mark A. Goldsmith Reports Disposal of Common Shares Worth $16.87 Million

Reuters
·
Aug 26

Revolution Medicines, Inc. : Bernstein Raises Target Price to $179 from $151

THOMSON REUTERS
·
Aug 21

Revolution Medicines Advances RASolve 308 Lung Cancer Trial, Raising Long-Term Upside Potential for RVMD

TIPRANKS
·
Aug 21

Movement Alert|Revolution Medicines, Inc. Rises 5.05% in Regular Trading, BeiGene RAS Inhibitor Collaboration Continues to Drive Momentum

Market Focus
·
Aug 18

Cullinan Climbs as Lung Cancer Drug Meets Late-Stage Trial Goal

Reuters
·
Aug 13